Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is listed today as Gain Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2020 | $10 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Gain Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2020).
SEC Form D · Jul 2020
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jul 2020
That is all the official record says: Gain Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Gain Therapeutics, Inc. are on record.
Investors#
No investor of Gain Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 48 investors.
Largest shareholders today
Institutions holding Gain Therapeutics, Inc. shares, as of Sep 30, 2026.
- Marshall Wace, LLP$3 M3.77%
- Potomac Capital Management, Inc.$2 M2.09%
- Jones Financial Companies Lllp$1 M1.66%
- Gsa Capital Partners LLP$1 M1.43%
- Cambridge Investment Research Advisors, Inc.$1 M1.27%
- DME Capital Management, LP$1 M1.27%
- Vanguard Capital Management LLC$1 M1.08%
- Geode Capital Management, LLC$1 M1.05%
- BlackRock, Inc.$0 M0.60%
- UBS Group AG$0 M0.54%
- Vanguard Fiduciary Trust Co$0 M0.52%
- Cresset Asset Management, LLC$0 M0.49%
- State Street Corp$0 M0.45%
- Renaissance Technologies LLC$0 M0.41%
- Citadel Advisors LLC$0 M0.38%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Eric I. Richman | Executive officer | Jul 2020 |
| Eric I. Richman | Director | Jul 2020 |
| Jeffrey I. Riley | Director | Jul 2020 |
| Khalid I. Islam | Director | Jul 2020 |
| Lorenzo I. Leoni | Proceeds may be used to pay for overhead and expenses which may include salaries. | Jul 2020 |
| Marianne I. Bjordal | Director | Jul 2020 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.